Novartis says it buried studies

Share this article:

Novartis says it failed to reveal 10,000 reports of side effects. The Wall Street Journal reports that the drugmaker says it has identified at least 10,000 cases which may never have been reported and which span a variety of drugs, including Gleevec, Tasigna, Exelon and Xolair.

Novartis tells the WSJ it has passed along this information to the Japanese Ministry of Health Labor and Welfare and the FDA, among others.

Novartis has been working against a series of bad PR moments, and this latest one compounds a problem highlighted two months ago, when Novartis said it had shredded or deleted some safety reports surrounding leukemia medications Gleevec and Tasigna.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.